SAN CLEMENTE, Calif.--(BUSINESS WIRE)--FRESCA Medical, Inc., a privately held sleep solutions and connected health company, announced today that Senior Director of Business Development, Ed McCarthy, will present at the 17th Annual New York Venture Summit. The summit will take place on July 18 and 19 in New York City. Mr. McCarthy will present and provide an overview of the company’s CURVE™ System, a clinically proven, patient-friendly and ergonomically-elegant solution to treat obstructive sleep apnea (OSA), on Wednesday, July 19 at 11:40 a.m. ET.
“As a California-based company, we are honored to present at this year’s New York Venture Summit. This summit provides us with an outstanding forum on the east coast to present our groundbreaking sleep apnea technology and value propositions for patients, providers and investors,” said Ed McCarthy. “The CURVE™ System will help transform the user experience in a therapeutic category that has been plagued by patient dissatisfaction and treatment abandonment. Our breakthrough is to achieve the positive airway pressure patients need without the intolerable high airflow associated with current therapies.”
FRESCA Medical’s current Series C financing is led by a recognized leader in the respiratory industry based in Asia. This investment also includes a royalty-bearing distribution agreement for the high-value sleep technology markets in China and Japan. FRESCA Medical is currently seeking $2 million to close the $6 million financing round. Closure of the Series C round enables the company to set up manufacturing, enroll patient preference studies, and secure regulatory clearance in the US, EU and China.
About FRESCA Medical, Inc.
FRESCA Medical, a California-based sleep solutions and connected health company, has developed a game-changing system to address the needs of over 100 million individuals around the world suffering from obstructive sleep apnea (OSA)1. The CURVE™ System with SmartValve™ technology provides patients with the positive airway pressure they need, while offering a more natural and comfortable breathing experience. The simple and elegant user interface sets a new standard for comfort and efficacy in an $8 billion therapeutic category where only 20% of sufferers have been diagnosed.2 FRESCA is embedding the concepts of Connected Health and the Internet of Medical Things (IoMT) into everything they do. The company seeks to empower patients with enhanced solutions and advanced technology enabling OSA sufferers to fulfill the FRESCA mission: “Reclaim Your Night!”
About Obstructive Sleep Apnea (OSA)
Approximately 30 million Americans suffer from obstructive sleep apnea (OSA), and 80 percent of the cases of OSA remain undiagnosed.2 This debilitating disease can affect people of any age and, if untreated, it has a significant negative impact on daily quality of life and long-term health. Currently, continuous positive airway pressure, or CPAP is the most widely used treatment for OSA in adults. CPAP has been proven to be effective, but it comes with some significant drawbacks. CPAP works by forcing a high rate of continuous airflow into the patient’s airway, which is very difficult for many patients to tolerate and leads to an unacceptable rate of treatment abandonment of more than 50 percent.3 A 2015 analysis commissioned by the American Academy of Sleep Medicine estimated that the total cost to society in the U.S. alone from undiagnosed OSA is $149.6 billion4, making it one of the most poorly managed preventable burdens to our healthcare system. To improve outcomes, sleep medicine has rapidly emerged as the leading discipline for connected health, cloud-based patient management and the Internet of Medical Things (IoMT). FRESCA Medical is dedicated to the paradigm-shift to fully-integrated, connected healthcare.
1 Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007: p.14
2 American Sleep Apnea Association Website. Sleep Apnea Information for Clinicians. Access on July 13, 2017: https://www.sleepapnea.org/learn/sleep-apnea-information-clinicians/
3 Weaver TE, Sawyer AM. Adherence to continuous positive airway pressure treatment for obstructive sleep apnoea: implications for future interventions. Indian J Med Res. 2010;131:245–258.
4 http://www.aasmnet.org/Resources/pdf/sleep-apnea-economic-crisis.pdf
Investors
FRESCA Medical, Inc.
John A. Cox
jcox@frescamed.com
